Breast cancer affects ~1 million new women yearly. Overexpression of ErbB2, a member of the EGFR family, is a causative factor in 30% of these cases and is targeted by the cancer drug Herceptin. Strikingly, studies of ErbB2 and the Drosophila EGFR have uncovered a close structural relationship. Using domain swaps between dEGFR and ErbB2, I have been investigating inhibition of dEGFR by the transmembrane molecule Kekkon1 with the hope that such insight may lead to novel cancer drugs.

• This report represents the work of one or more WPI undergraduate students submitted to the faculty as evidence of completion of a degree requirement. WPI routinely publishes these reports on its website without editorial or peer review.

Creator

• Afezolli, Debora

Contributori

• Gautam, Aditi

Publisher

• Worcester Polytechnic Institute

Identifier

• E-project-042910-153945

Advisor

• Duffy, Joseph B.

Year

• 2010

Date created

• 2010-04-29

Resource type

• Major Qualifying Project

Major

• Biology & Biotechnology

Rights statement

• In Copyright